CALPROTECT is developing a treatment able to reduce the heart injury and the risk of heart failure following myocardial infarction (heart attack). Based on innovative protein blockers, the treatment inhibits the excessive cardiac inflammation that occurs after myocardial infarction, leading to improved heart function.

Alexandru Schiopu, MD PhD

Founder & CEO

Lund University Associate professor Alexandru Schiopu is a consultant in Internal medicine and specialist in Cardiology at Skåne University Hospital in Lund, Sweden. CALPROTECT was founded to enable development of an immunomodulatory treatment against acute inflammation in MI that was discovered in the laboratory of Dr. Schiopu. In 2020, Dr. Alexandru Schiopu has been awarded the Prince Daniel Research Grant from the Heart and Lung Foundation and has won the first prize in the Lund University Innovation competition for his groundbreaking work that forms the foundation of CALPROTECT.